title: Cervical and vulvar cancer risk in relation to the joint effects of cigarette smoking and genetic variation in interleukin 2.
abstract: Cigarette smoking is an established cofactor to human papillomavirus (HPV) in the development of cervical and vulvar squamous cell carcinoma (SCC), and may influence risk through an immunosuppressive pathway. Genetic variation in interleukin 2 (IL2), associated in some studies with the inhibition of HPV-targeted immunity, may modify the effect of smoking on the risk of HPV-related anogenital cancers. We conducted a population-based case-only study to measure the departure from a multiplicative joint effect of cigarette smoking and IL2 variation on cervical and vulvar SCC. Genotyping of the four IL2 tagSNPs (rs2069762, rs2069763, rs2069777, and rs2069778) was done in 399 cervical and 486 vulvar SCC cases who had been interviewed regarding their smoking history. Compared with cases carrying the rs2069762 TT genotype, we observed significant departures from multiplicativity for smoking and carriership of the TG or GG genotypes in vulvar SCC risk [interaction odds ratio (IOR), 1.67; 95% confidence interval (CI), 1.16-2.41]. Carriership of one of three diplotypes, together with cigarette smoking, was associated with either a supramultiplicative (TGCT/GGCC; IOR, 2.09; 95% CI, 0.98-4.46) or submultiplicative (TTCC/TGTC; IOR, 0.37; 95% CI, 0.16-0.85 or TGCT/TGCC; IOR, 0.37; 95% CI, 0.15-0.87) joint effect in vulvar cancer risk. For cervical SCC, departure from multiplicativity was observed for smokers homozygous for the rs2069763 variant allele (TT versus GG or GT genotypes; IOR, 1.87; 95% CI, 1.00-3.48), and for carriership of the TTCC/TTCC diplotype (IOR, 2.08; 95% CI, 1.01-4.30). These results suggest that cervical and vulvar SCC risk among cigarette smokers is modified by genetic variation in IL2.
authors.affiliation: Program in Epidemiology, Division of Public Health Sciences, University of Washington, Seattle, WA, USA. skhussain@ucla.edu
authors.forename: Shehnaz K
authors.initials: SK
authors.lastname: Hussain
authors.forename: Margaret M
authors.initials: MM
authors.lastname: Madeleine
authors.forename: Lisa G
authors.initials: LG
authors.lastname: Johnson
authors.forename: Qin
authors.initials: Q
authors.lastname: Du
authors.forename: Mari
authors.initials: M
authors.lastname: Malkki
authors.forename: Hui-Wen
authors.initials: HW
authors.lastname: Wilkerson
authors.forename: Federico M
authors.initials: FM
authors.lastname: Farin
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Carter
authors.forename: Denise A
authors.initials: DA
authors.lastname: Galloway
authors.forename: Janet R
authors.initials: JR
authors.lastname: Daling
authors.forename: Effie W
authors.initials: EW
authors.lastname: Petersdorf
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Schwartz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000483:Alleles; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D015994:Incidence; D007376:Interleukin-2 / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011379:Prognosis; D012189:Retrospective Studies; D012907:Smoking / Q000009:adverse effects* / Q000097:blood / Q000453:epidemiology; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D014846:Vulvar Neoplasms / Q000097:blood / Q000453:epidemiology* / Q000209:etiology; D014861:Washington / Q000453:epidemiology; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; D007376:Interleukin-2